Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -87.01% | -81.87% | -73.16% | -68.31% | -66.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.01% | -81.87% | -73.16% | -68.31% | -66.58% |
| Cost of Revenue | -72.57% | -68.16% | -74.92% | -67.00% | -71.72% |
| Gross Profit | -121.02% | -108.76% | -66.72% | -72.68% | -41.46% |
| SG&A Expenses | -34.82% | -30.27% | -16.39% | -3.53% | -10.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 196.11% |
| Total Operating Expenses | -34.03% | -28.44% | -32.66% | -24.94% | -17.73% |
| Operating Income | 13.24% | -8.48% | -7.83% | -34.15% | -93.01% |
| Income Before Tax | -99.98% | -145.30% | -207.60% | -221.65% | -42.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.98% | -145.30% | -207.60% | -221.65% | -42.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.98% | -145.30% | -207.60% | -221.65% | -42.74% |
| EBIT | 13.24% | -8.48% | -7.83% | -34.15% | -93.01% |
| EBITDA | 9.59% | -3.23% | 6.14% | -13.33% | -56.89% |
| EPS Basic | -101.33% | -148.39% | -212.77% | -226.88% | -44.23% |
| Normalized Basic EPS | -13.68% | -41.77% | -73.33% | -86.44% | -43.94% |
| EPS Diluted | -73.33% | -140.79% | -167.21% | -186.61% | -52.17% |
| Normalized Diluted EPS | -13.68% | -41.77% | -73.33% | -86.44% | -43.94% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |